{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:25:19Z","timestamp":1770834319369,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.urology.2010.03.028","type":"journal-article","created":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T08:21:25Z","timestamp":1288945285000},"page":"1267.e1-1267.e6","source":"Crossref","is-referenced-by-count":9,"title":["Enhanced Antitumor Effect of Coincident Intravesical Gemcitabine Plus BCG Therapy in an Orthotopic Bladder Cancer Model"],"prefix":"10.1016","volume":"76","author":[{"given":"Minoru","family":"Horinaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Yanaihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Nakahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2010.03.028_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2010.03.028_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0094-0143(05)70238-X","article-title":"The potential role of gene therapy in the treatment of bladder cancer","volume":"27","author":"Hsieh","year":"2000","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2010.03.028_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.03.028_bib4","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2010.03.028_bib5","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2010.03.028_bib6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2010.03.028_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.gt.3301157","article-title":"Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model","volume":"7","author":"Horiguchi","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.urology.2010.03.028_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1440-1746.2006.04496.x","article-title":"Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells","volume":"22","author":"Jacob","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.urology.2010.03.028_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","article-title":"A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.03.028_bib10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.03.028_bib11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0022-5347(01)67427-5","article-title":"Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder","volume":"153","author":"Lamm","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.03.028_bib12","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","article-title":"BCG immunotherapy of bladder cancer: 20 years on","volume":"353","author":"Alexandroff","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2010.03.028_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","article-title":"Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer","volume":"55","author":"Brake","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urology.2010.03.028_bib14","first-page":"2629","article-title":"Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs","volume":"5","author":"Cozzi","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2010.03.028_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2010.03.028_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urology.2010.03.028_bib17","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2010.03.028_bib18","doi-asserted-by":"crossref","first-page":"7477","DOI":"10.1158\/0008-5472.CAN-06-4639","article-title":"A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model","volume":"67","author":"Ko","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2010.03.028_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1086\/314065","article-title":"Role of animal models in understanding intravesical therapy with Bacille Calmette-Guerin","volume":"31","author":"Ratliff","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.urology.2010.03.028_bib20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.juro.2007.11.045","article-title":"The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study","volume":"179","author":"Pan","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.03.028_bib21","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.juro.2007.08.063","article-title":"Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy","volume":"178","author":"DiPaola","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.03.028_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000283049","article-title":"Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro?","volume":"59","author":"Sasaki","year":"1997","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2010.03.028_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0046-8177(96)90107-0","article-title":"Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas","volume":"27","author":"Langford","year":"1996","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urology.2010.03.028_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-5347(01)64485-9","article-title":"Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer","volume":"158","author":"Asakura","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.03.028_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.11049","article-title":"Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification","volume":"105","author":"Santos","year":"2003","journal-title":"Int J Cancer"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510003651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510003651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:27:31Z","timestamp":1711931251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429510003651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0090429510003651"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2010.03.028","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}